Atle Fund Management AB Sells 4,835 Shares of Cencora, Inc. $COR

Atle Fund Management AB lessened its holdings in shares of Cencora, Inc. (NYSE:COR) by 16.9% in the fourth quarter, Holdings Channel.com reports. The firm owned 23,773 shares of the company’s stock after selling 4,835 shares during the period. Cencora comprises about 2.5% of Atle Fund Management AB’s investment portfolio, making the stock its 14th biggest position. Atle Fund Management AB’s holdings in Cencora were worth $8,029,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Marshall Wace LLP lifted its holdings in shares of Cencora by 518.9% in the third quarter. Marshall Wace LLP now owns 1,995,118 shares of the company’s stock worth $623,534,000 after buying an additional 1,672,762 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Cencora by 528.9% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,475,859 shares of the company’s stock worth $461,250,000 after buying an additional 1,241,186 shares in the last quarter. Viking Global Investors LP lifted its holdings in shares of Cencora by 95.0% in the second quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock worth $624,207,000 after buying an additional 1,013,913 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Cencora by 4.1% in the third quarter. Vanguard Group Inc. now owns 23,395,547 shares of the company’s stock worth $7,311,810,000 after buying an additional 916,506 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Cencora by 21.3% in the third quarter. JPMorgan Chase & Co. now owns 4,677,797 shares of the company’s stock worth $1,461,965,000 after buying an additional 821,098 shares in the last quarter. Institutional investors own 97.52% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Barclays increased their price target on shares of Cencora from $400.00 to $425.00 and gave the stock an “overweight” rating in a report on Friday, February 13th. Morgan Stanley set a $342.00 target price on shares of Cencora in a research note on Friday, May 8th. UBS Group raised their target price on shares of Cencora from $410.00 to $412.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Leerink Partners reiterated an “outperform” rating on shares of Cencora in a report on Tuesday, March 17th. Finally, Jefferies Financial Group upgraded shares of Cencora from an “underperform” rating to a “buy” rating in a report on Thursday, January 22nd. Twelve analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $380.25.

Cencora Trading Up 1.6%

COR stock opened at $266.03 on Wednesday. Cencora, Inc. has a 1-year low of $244.82 and a 1-year high of $377.54. The company has a debt-to-equity ratio of 3.40, a current ratio of 0.95 and a quick ratio of 0.59. The company has a market capitalization of $51.76 billion, a price-to-earnings ratio of 20.40, a PEG ratio of 1.21 and a beta of 0.64. The business has a 50 day simple moving average of $310.87 and a two-hundred day simple moving average of $338.24.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.07). Cencora had a return on equity of 135.20% and a net margin of 0.78%.The business had revenue of $78.36 billion during the quarter, compared to the consensus estimate of $81.09 billion. During the same quarter in the previous year, the company earned $4.42 earnings per share. The company’s revenue for the quarter was up 3.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Research analysts anticipate that Cencora, Inc. will post 17.76 EPS for the current fiscal year.

Cencora Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 1st. Investors of record on Friday, May 15th will be issued a $0.60 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.9%. Cencora’s dividend payout ratio (DPR) is 18.40%.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.